SG11201702656WA - Anti-tnf compounds - Google Patents
Anti-tnf compoundsInfo
- Publication number
- SG11201702656WA SG11201702656WA SG11201702656WA SG11201702656WA SG11201702656WA SG 11201702656W A SG11201702656W A SG 11201702656WA SG 11201702656W A SG11201702656W A SG 11201702656WA SG 11201702656W A SG11201702656W A SG 11201702656WA SG 11201702656W A SG11201702656W A SG 11201702656WA
- Authority
- SG
- Singapore
- Prior art keywords
- tnf compounds
- tnf
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462060424P | 2014-10-06 | 2014-10-06 | |
PCT/US2015/054288 WO2016057549A1 (en) | 2014-10-06 | 2015-10-06 | Anti-tnf compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201702656WA true SG11201702656WA (en) | 2017-04-27 |
Family
ID=55653658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201702656WA SG11201702656WA (en) | 2014-10-06 | 2015-10-06 | Anti-tnf compounds |
Country Status (18)
Country | Link |
---|---|
US (3) | US10208310B2 (en) |
EP (1) | EP3204499A4 (en) |
JP (1) | JP6741673B2 (en) |
KR (1) | KR20170063949A (en) |
CN (1) | CN107002081A (en) |
AU (1) | AU2015328242A1 (en) |
BR (1) | BR112017007012A2 (en) |
CA (1) | CA2963931A1 (en) |
CL (1) | CL2017000806A1 (en) |
CO (1) | CO2017004314A2 (en) |
CR (1) | CR20170181A (en) |
EA (1) | EA201790802A1 (en) |
IL (1) | IL251508A0 (en) |
MX (1) | MX2017004448A (en) |
PE (1) | PE20170694A1 (en) |
PH (1) | PH12017500601A1 (en) |
SG (1) | SG11201702656WA (en) |
WO (1) | WO2016057549A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
AU2014292926B2 (en) | 2013-07-25 | 2020-03-05 | Exicure Operating Company | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
CA2932122C (en) | 2013-12-03 | 2022-04-19 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
CR20170181A (en) | 2014-10-06 | 2017-05-31 | Exicure Inc | ANTI-TNF COMPOUNDS |
AU2015349680A1 (en) | 2014-11-21 | 2017-06-08 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
CA2973702A1 (en) * | 2015-01-14 | 2016-07-21 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
WO2016149323A1 (en) * | 2015-03-16 | 2016-09-22 | Exicure, Inc. | Immunomodulatory spherical nucleic acids |
US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
US20190142739A1 (en) * | 2016-04-19 | 2019-05-16 | Exicure, Inc. | Topical administration of therapeutic agents and oligonucleotide formulations |
EP3452598A4 (en) * | 2016-05-06 | 2020-04-29 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
MX2020000387A (en) | 2017-07-13 | 2020-08-17 | Univ Northwestern | General and direct method for preparing oligonucleotide-functiona lized metal-organic framework nanoparticles. |
US20220362398A1 (en) * | 2019-04-26 | 2022-11-17 | Exicure Operating Company | Administration of spherical nucleic acids for ophthalmological uses |
CN110385427B (en) * | 2019-07-31 | 2021-10-19 | 东南大学 | Water-soluble nano particle and preparation method and application thereof |
Family Cites Families (142)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955589A (en) | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
FR2677272B1 (en) | 1991-06-05 | 1995-03-03 | Biovecteurs As | PARTICULATE VECTOR WITH SELECTIVE TROPISM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION. |
US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
DE69305160T2 (en) | 1992-04-22 | 1997-04-30 | Ecole Polytech | LIPID MEMBRANES FOR BIOSENSOR APPLICATIONS |
US5472881A (en) | 1992-11-12 | 1995-12-05 | University Of Utah Research Foundation | Thiol labeling of DNA for attachment to gold surfaces |
US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
PT772619E (en) | 1994-07-15 | 2006-10-31 | Univ Iowa Res Found | OLIGONUCLEOTIDOS IMUNOMODULADORES |
AU3379597A (en) | 1996-06-19 | 1998-01-07 | Hybridon, Inc. | Modulation of tetraplex formation by chemical modifications of a g4-containing oligonucleotide |
US6506564B1 (en) | 1996-07-29 | 2003-01-14 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6361944B1 (en) | 1996-07-29 | 2002-03-26 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
EP1818417B1 (en) | 1996-07-29 | 2014-02-12 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
EP0856579A1 (en) | 1997-01-31 | 1998-08-05 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | An antisense oligonucleotide preparation method |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6228642B1 (en) | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
DE60041971D1 (en) | 1999-07-08 | 2009-05-20 | Cap Biotechnology Inc | CALCIUM-CONTAINING STRUCTURES AND METHOD FOR THE PRODUCTION AND USE THEREOF |
US6585947B1 (en) | 1999-10-22 | 2003-07-01 | The Board Of Trustess Of The University Of Illinois | Method for producing silicon nanoparticles |
EP1238071B1 (en) | 1999-11-29 | 2008-04-23 | Avi Biopharma, Inc. | Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses |
US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
BR0115475A (en) | 2000-11-20 | 2004-02-10 | Univ Illinois | Membrane structuring proteins |
US7083958B2 (en) | 2000-11-20 | 2006-08-01 | The Board Of Trustees Of The University Of Illinois | Membrane scaffold proteins |
GB0111279D0 (en) | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
WO2002096262A2 (en) | 2001-05-25 | 2002-12-05 | Northwestern University | Non-alloying core shell nanoparticles |
JP2005511761A (en) | 2001-07-10 | 2005-04-28 | ノース・キャロライナ・ステイト・ユニヴァーシティ | Nanoparticle delivery vehicle |
US20030044354A1 (en) | 2001-08-16 | 2003-03-06 | Carpenter Alan P. | Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release |
EP2213737B1 (en) | 2002-02-01 | 2012-11-07 | Life Technologies Corporation | Double-stranded oligonucleotides |
NZ534496A (en) | 2002-02-06 | 2006-08-31 | Univ Johns Hopkins | Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts |
JP2006502976A (en) | 2002-05-17 | 2006-01-26 | エスペリオン セラピューティクス,インコーポレイテッド | Methods and compositions for treating ischemia-reperfusion |
AU2003303954A1 (en) | 2002-10-25 | 2004-10-11 | Emory University | Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring |
US20040158051A1 (en) | 2002-11-19 | 2004-08-12 | Mihri Ozkan | Mono and dual conjugation of nanostructures and methods of making and using thereof |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
EP1547581A1 (en) | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
US8097283B2 (en) | 2004-01-15 | 2012-01-17 | Mount Sinai School Of Medicine | Methods and compositions for imaging |
WO2005108614A2 (en) | 2004-04-07 | 2005-11-17 | Northwestern University | Reversible and chemically programmable micelle assembly with dna block-copolymer amphiphiles |
WO2006033679A2 (en) | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
EP1604669A1 (en) | 2004-06-10 | 2005-12-14 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of ATP analogues for treatment of cardiovascular diseases |
WO2006016978A1 (en) | 2004-06-30 | 2006-02-16 | Applera Corporation | Analog probe complexes |
US20060083781A1 (en) | 2004-10-14 | 2006-04-20 | Shastri V P | Functionalized solid lipid nanoparticles and methods of making and using same |
US8211712B2 (en) | 2005-03-29 | 2012-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Method of fabricating lipid bilayer membranes on solid supports |
WO2006124089A1 (en) | 2005-05-12 | 2006-11-23 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Self-assembled nucleic acid nanoarrays and uses therefor |
AU2006249323B2 (en) | 2005-05-27 | 2012-08-30 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
JP2009500412A (en) | 2005-07-07 | 2009-01-08 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Combination therapy of anti-CTLA-4 antibody and CPG motif-containing synthetic oligodeoxynucleotide for the treatment of cancer |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
WO2007067733A2 (en) | 2005-12-09 | 2007-06-14 | Massachusetts Institute Of Technology | Compositions and methods to monitor rna delivery to cells |
WO2007089607A2 (en) | 2006-01-26 | 2007-08-09 | University Of Massachusetts | Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same |
WO2007106683A2 (en) | 2006-03-10 | 2007-09-20 | The Trustees Of The University Of Pennsylvania | Biomimetic iron-oxide-containing lipoprotein and related materials |
WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
JP2010507361A (en) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn as an immunostimulant / adjuvant |
AU2007286203B2 (en) | 2006-08-08 | 2013-05-02 | Board Of Regents, The University Of Texas System | Multistage delivery of active agents |
US7976743B2 (en) | 2006-10-16 | 2011-07-12 | Northwestern University | Gas-containing liposomes |
CA2679586A1 (en) | 2007-02-27 | 2008-10-23 | Northwestern University | Molecule attachment to nanoparticles |
WO2008106660A2 (en) | 2007-03-01 | 2008-09-04 | Invitrogen Corporation | Isolated phospholipid-protein particles |
UA100375C2 (en) | 2007-03-30 | 2012-12-25 | Хірофумі Такеуті | Transpulmonary liposome for controlling drug arrival |
US9950830B2 (en) | 2007-04-23 | 2018-04-24 | Coldkeepers, Llc | Insulated liners and containers |
CA2689923A1 (en) | 2007-05-30 | 2008-12-11 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
WO2009012786A2 (en) * | 2007-07-23 | 2009-01-29 | Aarhus Universitet | Nanoparticle-mediated treatment for inflammatory diseases |
US8563527B2 (en) | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
WO2009049208A1 (en) | 2007-10-12 | 2009-04-16 | The University Of North Carolina At Chapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
EP2217221B1 (en) | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
CN101970687A (en) | 2007-11-09 | 2011-02-09 | 东北大学 | Self-assembling micelle-like nanoparticles for systemic gene delivery |
CN102027019A (en) | 2007-12-12 | 2011-04-20 | 大学健康网络 | High-density lipoprotein-like peptide-phospholipid scaffold (''HPPS'') nanoparticles |
WO2009089117A1 (en) | 2008-01-04 | 2009-07-16 | Hormel Foods Corporation | Encapsulation of oxidatively unstable compounds |
EP2257313A2 (en) | 2008-02-21 | 2010-12-08 | University of Kentucky Research Foundation | Ultra-small rnas as toll-like receptor-3 antagonists |
EP2105145A1 (en) | 2008-03-27 | 2009-09-30 | ETH Zürich | Method for muscle-specific delivery lipid-conjugated oligonucleotides |
US20110151000A1 (en) | 2008-04-21 | 2011-06-23 | Schultz William J | Nitric oxide-releasing compositions, devices and methods |
CA3013503A1 (en) | 2008-04-25 | 2009-10-29 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
US8063131B2 (en) | 2008-06-18 | 2011-11-22 | University Of Washington | Nanoparticle-amphipol complexes for nucleic acid intracellular delivery and imaging |
WO2010014572A2 (en) | 2008-07-28 | 2010-02-04 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 9 expression by antisense oligonucleotides |
WO2010017154A2 (en) | 2008-08-04 | 2010-02-11 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 3 expression by antisense oligonucleotides |
US20100047188A1 (en) | 2008-08-04 | 2010-02-25 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
US20130090457A1 (en) | 2008-10-31 | 2013-04-11 | Janssen Biotech, Inc. | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
KR101692880B1 (en) | 2008-11-24 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | Polyvalent rna-nanoparticle compositions |
US20100184844A1 (en) | 2009-01-08 | 2010-07-22 | Northwestern University | Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2010085959A1 (en) | 2009-01-28 | 2010-08-05 | Aarhus Universitet | Treatment of radiation-induced fibrosis |
EP2406379A4 (en) | 2009-03-13 | 2012-09-26 | Egen Inc | Compositions and methods for the delivery of biologically active rnas |
AU2010237001B2 (en) | 2009-04-15 | 2016-07-07 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
WO2011017382A2 (en) | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Nanofibers and morphology shifting micelles |
US20120277283A1 (en) | 2009-08-04 | 2012-11-01 | Mirkin Chad A | Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications |
WO2011017690A2 (en) | 2009-08-07 | 2011-02-10 | Northwestern University | Intracellular delivery of contrast agents with functionalized nanoparticles |
WO2011028847A1 (en) | 2009-09-01 | 2011-03-10 | Northwestern University | Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent |
EP2473160A4 (en) | 2009-09-01 | 2015-06-03 | Univ Northwestern | Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers |
KR101132626B1 (en) | 2009-10-12 | 2012-04-02 | 주식회사 녹십자 | Method for preparing HDL nanoparticles for the delivery of hydrophobic drugs |
US20110111974A1 (en) | 2009-10-23 | 2011-05-12 | Northwestern University | Short Duplex Probes for Enhanced Target Hybridization |
KR20120136345A (en) | 2009-10-30 | 2012-12-18 | 노오쓰웨스턴 유니버시티 | Templated nanoconjugates |
WO2011072133A1 (en) | 2009-12-09 | 2011-06-16 | William Marsh Rice University | Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles |
CA2784547A1 (en) | 2009-12-23 | 2011-06-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Influenza targets |
US20130178610A1 (en) | 2009-12-24 | 2013-07-11 | Chad A. Mirkin | Oligonucleotide specific uptake of nanoconjugates |
WO2011091065A2 (en) | 2010-01-19 | 2011-07-28 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
EP2399608B1 (en) | 2010-03-05 | 2020-07-08 | Sebastian Fuchs | Immunomodulating nanoparticulate composition for use in inhalation therapy |
US20130101512A1 (en) | 2010-03-12 | 2013-04-25 | Chad A. Mirkin | Crosslinked polynucleotide structure |
WO2011127405A1 (en) | 2010-04-08 | 2011-10-13 | Sanford-Burnham Medical Research Institute | Methods and compositions for enhanced delivery of compounds |
KR101198715B1 (en) | 2010-05-14 | 2012-11-13 | 한국생명공학연구원 | Asymmetric liposomes with higher encapsulation efficiency of nucleic acids and hydrophilic anion chemicals |
US20140134658A1 (en) | 2010-05-21 | 2014-05-15 | Notrhwestern University, An Illinois Not For Profit Corporation | Psa enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness |
WO2011156895A2 (en) | 2010-06-14 | 2011-12-22 | National Research Council Of Canada | Magnetic nanoparticles and uses thereof |
GB201014026D0 (en) | 2010-08-20 | 2010-10-06 | Ucl Business Plc | Treatment |
US9687447B2 (en) | 2010-10-26 | 2017-06-27 | Ac Immune S.A. | Method for preparing liposome-based constructs |
AU2011329668B2 (en) | 2010-11-19 | 2016-07-28 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response |
PT2663555T (en) | 2011-01-12 | 2017-03-23 | Array Biopharma Inc | Substituted benzoazepines as toll-like receptor modulators |
US9693957B2 (en) | 2011-07-08 | 2017-07-04 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
WO2013012628A2 (en) | 2011-07-15 | 2013-01-24 | The University Of Georgia Research Foundation, Inc. | Immune-stimulating photoactive hybrid nanoparticles |
EP2750662A4 (en) | 2011-08-31 | 2015-06-24 | Univ Georgia | Apoptosis-targeting nanoparticles |
CN104024854A (en) | 2011-09-11 | 2014-09-03 | 奥拉森斯有限责任公司 | Cellular Uptake Control Systems |
CN104244965A (en) | 2012-02-22 | 2014-12-24 | 西北大学 | Nanostructures for treating cancers and other conditions |
WO2013151771A1 (en) | 2012-04-05 | 2013-10-10 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
WO2014025795A1 (en) | 2012-08-07 | 2014-02-13 | Northeastern University | Compositions for the delivery of rna and drugs into cells |
US9095625B2 (en) | 2012-08-31 | 2015-08-04 | University Of Massachusetts | Graft-copolymer stabilized metal nanoparticles |
WO2014120379A1 (en) | 2013-01-31 | 2014-08-07 | Privail Inc. | Testing device |
WO2014169264A2 (en) | 2013-04-11 | 2014-10-16 | The Board Of Trustees Of The University Of Illinois | Nanoparticle mediated delivery of sirna |
AU2014292928A1 (en) | 2013-07-25 | 2016-03-03 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunoregulatory agents |
AU2014292926B2 (en) | 2013-07-25 | 2020-03-05 | Exicure Operating Company | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
CA2932122C (en) | 2013-12-03 | 2022-04-19 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
EP3129391A4 (en) | 2014-04-03 | 2017-12-20 | Exicure, Inc. | Self assembling nucleic acid nanostructures |
CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
TW201620526A (en) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
CR20170181A (en) | 2014-10-06 | 2017-05-31 | Exicure Inc | ANTI-TNF COMPOUNDS |
US10517924B2 (en) | 2014-11-24 | 2019-12-31 | Northwestern University | High density lipoprotein nanoparticles for inflammation |
US9397424B2 (en) | 2014-11-25 | 2016-07-19 | Tyco Electronics Corporation | Connector assembly for electrically coupling a module card to a circuit board |
EP3633908B1 (en) | 2014-12-23 | 2021-08-11 | LG Electronics Inc. | Method for reporting channel state information in wireless access system supporting unlicensed bands, and apparatus supporting same |
CA2973702A1 (en) | 2015-01-14 | 2016-07-21 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
US20180042848A1 (en) | 2015-02-18 | 2018-02-15 | Exicure, Inc. | Immuno-regulatory lipid containing spherical nucleic acids |
WO2016149323A1 (en) | 2015-03-16 | 2016-09-22 | Exicure, Inc. | Immunomodulatory spherical nucleic acids |
US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
EP3322407A4 (en) | 2015-07-14 | 2019-07-10 | Exicure, Inc. | Spherical nucleic acid (sna)-mediated delivery of lipid-complexes to cells |
US10426842B2 (en) | 2015-07-15 | 2019-10-01 | The Curators Of The University Of Missouri | Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug |
AU2016312530A1 (en) | 2015-08-24 | 2018-03-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
US20170240960A1 (en) | 2016-02-24 | 2017-08-24 | Aurasense, Llc | Spherical nucleic acids (sna) flare based fluorescence in situ hybridization |
US20190142739A1 (en) | 2016-04-19 | 2019-05-16 | Exicure, Inc. | Topical administration of therapeutic agents and oligonucleotide formulations |
US10967072B2 (en) | 2016-04-27 | 2021-04-06 | Northwestern University | Short interfering RNA templated lipoprotein particles (siRNA-TLP) |
JP2019521652A (en) | 2016-05-06 | 2019-08-08 | イグジキュア, インコーポレーテッドExicure, Inc. | TLR9 agonist of globular nucleic acid |
TW201808283A (en) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | Nitrogen-containing tricyclic compounds and uses thereof in medicine |
WO2018039106A1 (en) | 2016-08-22 | 2018-03-01 | Stemco Products, Inc. | Double wishbone independent trailer suspension |
WO2019168558A1 (en) | 2018-02-28 | 2019-09-06 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
US20210002640A1 (en) | 2018-02-28 | 2021-01-07 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors |
WO2019246409A1 (en) | 2018-06-20 | 2019-12-26 | Exicure, Inc. | Il-1 beta targeting spherical nucleic acids |
-
2015
- 2015-10-06 CR CR20170181A patent/CR20170181A/en unknown
- 2015-10-06 MX MX2017004448A patent/MX2017004448A/en unknown
- 2015-10-06 EA EA201790802A patent/EA201790802A1/en unknown
- 2015-10-06 WO PCT/US2015/054288 patent/WO2016057549A1/en active Application Filing
- 2015-10-06 BR BR112017007012A patent/BR112017007012A2/en not_active Application Discontinuation
- 2015-10-06 AU AU2015328242A patent/AU2015328242A1/en not_active Abandoned
- 2015-10-06 CA CA2963931A patent/CA2963931A1/en not_active Abandoned
- 2015-10-06 JP JP2017538185A patent/JP6741673B2/en active Active
- 2015-10-06 EP EP15849111.8A patent/EP3204499A4/en not_active Withdrawn
- 2015-10-06 US US15/517,064 patent/US10208310B2/en active Active
- 2015-10-06 PE PE2017000552A patent/PE20170694A1/en not_active Application Discontinuation
- 2015-10-06 KR KR1020177012238A patent/KR20170063949A/en unknown
- 2015-10-06 SG SG11201702656WA patent/SG11201702656WA/en unknown
- 2015-10-06 CN CN201580060623.0A patent/CN107002081A/en active Pending
-
2017
- 2017-03-31 PH PH12017500601A patent/PH12017500601A1/en unknown
- 2017-04-02 IL IL251508A patent/IL251508A0/en unknown
- 2017-04-04 CL CL2017000806A patent/CL2017000806A1/en unknown
- 2017-04-28 CO CONC2017/0004314A patent/CO2017004314A2/en unknown
-
2019
- 2019-01-16 US US16/248,912 patent/US10760080B2/en active Active
-
2020
- 2020-07-16 US US16/930,977 patent/US20200339996A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200339996A1 (en) | 2020-10-29 |
EP3204499A1 (en) | 2017-08-16 |
WO2016057549A1 (en) | 2016-04-14 |
MX2017004448A (en) | 2017-10-23 |
US20190211338A1 (en) | 2019-07-11 |
US20170306331A1 (en) | 2017-10-26 |
CR20170181A (en) | 2017-05-31 |
AU2015328242A1 (en) | 2017-04-27 |
US10208310B2 (en) | 2019-02-19 |
EA201790802A1 (en) | 2017-08-31 |
PE20170694A1 (en) | 2017-05-26 |
EP3204499A4 (en) | 2018-04-25 |
CA2963931A1 (en) | 2016-04-14 |
JP6741673B2 (en) | 2020-08-19 |
BR112017007012A2 (en) | 2018-03-06 |
KR20170063949A (en) | 2017-06-08 |
CO2017004314A2 (en) | 2017-07-28 |
PH12017500601A1 (en) | 2017-09-25 |
JP2017531451A (en) | 2017-10-26 |
IL251508A0 (en) | 2017-05-29 |
CL2017000806A1 (en) | 2017-12-15 |
US10760080B2 (en) | 2020-09-01 |
CN107002081A (en) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250345B (en) | Novel compounds | |
IL250592A0 (en) | Novel compounds | |
IL251508A0 (en) | Anti-tnf compounds | |
AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
GB201417011D0 (en) | Novel compounds | |
GB201417094D0 (en) | Novel compounds | |
GB201417018D0 (en) | Novel compounds | |
GB201402431D0 (en) | Compounds | |
SG11201606693SA (en) | Novel compounds | |
GB201405991D0 (en) | Novel compounds | |
GB201411236D0 (en) | Novel compounds | |
GB201411239D0 (en) | Novel compounds | |
GB201404987D0 (en) | Compounds | |
GB201404002D0 (en) | Novel compounds | |
AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
IL248983A0 (en) | Novel compounds | |
GB201419102D0 (en) | Novel compounds | |
GB201405361D0 (en) | Compounds | |
ZA201605726B (en) | Novel compounds | |
GB201421834D0 (en) | Novel compounds | |
GB201421784D0 (en) | Novel compounds | |
GB201417043D0 (en) | Novel compounds | |
GB201417041D0 (en) | Novel compounds | |
GB201417021D0 (en) | Novel compounds | |
GB201414614D0 (en) | Novel compounds |